Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers reported that both progestin-only injectable contraceptives, DMPA-IM and NET-EN, significantly decreased serum testosterone and SHBG levels among HIV-negative women in South Africa, yet this did not explain prior findings of no reduction in risky sexual behavior or sexual function.

This source highlights the role of progestin in contraception, noting that while different types have varying progesteronic potential and effects, they share similar contraceptive mechanisms, allowing tailored use based on patient conditions.

Testosterone replacement therapy can prevent men from fathering children and should not be used by those wanting to stay fertile.

This review discusses the physiological basis, history, and current development of male hormonal contraception, highlighting its potential risks and benefits, but reports no new research findings.

This review examines the benefits and potential risks of androgen replacement therapy for male hypogonadism but reports no new clinical results; the authors highlight the need for careful risk assessment, especially in older men.

This study assessed contraceptive use among women in Mukalla city, Yemen, reporting that 78.7% experienced side effects such as hair loss and abnormal bleeding, with oral contraceptive pills being the most common method.

This review discusses the effectiveness and mechanisms of combined oral contraceptives in treating acne vulgaris but reports no new clinical results; the authors highlight their antiandrogenic effects for managing acne and related endocrine disorders.

This study suggests that the testosterone analogs 7α-Methyltestosterone and 7α-Ethyltestosterone may offer promising androgenic, progestogenic, and anabolic properties for development as male contraceptives.

This article reviews the potential clinical use of anabolic steroids in treating muscle loss from chronic diseases and aging and highlights both the benefits and risks of these substances in sports.

This review examines the scientific evidence on the short-term safety of testosterone therapy for treating hypoactive sexual desire disorder in women, without presenting new clinical results.

This review summarizes existing clinical guidelines for hormonal therapy in gender dysphoria, observing similarities in international practices and emphasizing the need for more evidence-based research, particularly on GnRH agonists for both trans women and men.

This review discusses the role of androgens in women's sexual health and highlights the need for further research on androgen replacement therapy to optimize quality of life, but reports no new clinical results.

This article presents guidelines developed by a multidisciplinary expert panel for the care of adolescent transgender and non-binary individuals with gender dysphoria, emphasizing individualized, affirmative care to enhance well-being and quality of life.

This article discusses the various roles of steroids in vertebrate organ systems and notes several glucocorticoids that were among the Top 200 Drugs by sales in the 2010s, but it reports no new clinical findings.

This review discusses treatments for female sexual dysfunction in postmenopausal women, noting that the effectiveness of current pharmaceutical options is inconclusive and emphasizing the importance of individualized care.

Testosterone therapy can improve sexual function in women but long-term safety is unclear.

This review discusses the clinical implications of female androgen deficiency and evaluates treatment options, emphasizing the need for cautious use of replacement therapy in women with severe deficiency and matching symptoms.

This review found that hormones significantly impact women's health and athletic performance, influencing the menstrual cycle, menopause, and exercise responses, while therapies like contraception and hormone replacement require personalized approaches to balance benefits and risks.

This review evaluates previous studies on androgen-progestin combinations for male contraception, concluding that long-acting injectable formulations appear promising due to their effectiveness and minimal short-term adverse effects.

This study found that cyclosporine-A might significantly increase the risk of cerebral venous and arterial thrombosis in patients with aplastic anemia.

This review highlights therapeutic options for inducing puberty in males and females with delayed puberty, emphasizing the need for larger trials to establish the best approaches.

This narrative review discusses the initiation and monitoring of gender-affirming hormone therapy in Australia, noting standard testosterone use for trans men and estradiol with anti-androgens for trans women, emphasizing the importance of monitoring cardiovascular and bone health.

This review discusses hormonal therapies for acne related to endocrine disorders and provides practical guidelines for managing hormonally influenced acne in clinical practice, but reports no new clinical results.

This review discusses the increased risk of venous thromboembolism associated with combined hormonal contraceptives, particularly noting higher risks with certain progestins like desogestrel, gestodene, and cyproterone acetate, but reports no new clinical findings.

This study found that A-ring reduced derivatives of norethisterone and levonorgestrel exhibit estrogen-like potency in rat osteoblasts, suggesting a mechanism for 19-norprogestins' bone restoration effects in postmenopausal women.

This review discusses the effects and selection criteria of different progestogens in various treatments but reports no direct clinical comparisons of their metabolic effects.

This study reports that among young women, combined oral contraceptives containing chlormadinone, among others, are associated with an increased risk of venous thromboembolism compared to those containing levonorgestrel with low ethinylestradiol.

In this study, Neogynon was found to be 100% effective as a contraceptive, with no observed failures in 3129 cycles among 184 women, while side effects included changes in endometrial patterns and some central nervous system effects.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This study found that a single 2 ml injection of TEEV every 4 weeks offers similar beneficial effects with fewer side effects compared to injecting the same dose every 2 weeks in postmenopausal women.